William N. Charman

ORCID: 0000-0002-7051-2023 · 5 papers in corpus
article 2007
·doi:10.1002/jps.21246

Lipid-based formulations of danazol with varying quantities of included surfactant have been examined in vitro and in vivo. Formulations comprising fatty acid ester surfactants were readily hydrolysed during in vitro digestion, although Cre…

article 2007
·doi:10.1007/s11095-006-9194-z

PurposeTo investigate the impact of a change in the proportions of lipid, surfactant and co-solvent on the solubilisation capacity of self-emulsifying formulations of danazol during in vitro dispersion and digestion studies and correlation …

article 2004
·doi:10.1023/b:pham.0000036914.22132.cc

PurposeTo investigate the impact of lipidic formulation type on in vitro dispersion and digestion properties and the relationship to oral bioavailability, using danazol as a model lipophilic poorly water-soluble drug.MethodsThree lipid-base…

article 1993
·doi:10.1002/j.1552-4604.1993.tb03921.x

The absorption of danazol (100 mg) after oral or intraintestinal administration to the proximal jejunum or proximal ileum has been studied in healthy female subjects. The extent of danazol absorption after administration as a solubilized gl…

article 1993
·doi:10.1002/j.1552-4604.1993.tb04673.x

The bioavailability of a single 100-mg dose of danazol delivered from the commercial formulation (hard gelatin capsule) and from an experimental lipid emulsion formulation of danazol was studied in 11 healthy female volunteers in both fed a…